- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | Inhibrx Biosciences reshuffles leadership, appoints new CSO and President | 1 | Investing.com | ||
| 01.04. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 17.03. | Inhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results | 100 | PR Newswire | SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth... ► Artikel lesen | |
| 17.03. | Inhibrx Biosciences GAAP EPS of -$3.09 misses by $0.21, revenue of $100K | 1 | Seeking Alpha | ||
| 17.03. | Inhibrx, Inc. Q4 Loss Decreases | 1 | RTTNews | ||
| 17.03. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | Inhibrx Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.01. | Inhibrx reports promising ozekibart trial results | 1 | Investing.com | ||
| 21.01. | Inhibrx meldet vielversprechende Ergebnisse der Ozekibart-Studie | 1 | Investing.com Deutsch | ||
| 21.01. | Inhibrx Biosciences, Inc.: Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer | 85 | PR Newswire | SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 21.01. | Inhibrx Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.01. | Inhibrx Biosciences enters $150M loan facility | 1 | Seeking Alpha | ||
| 13.01. | Inhibrx Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.11.24 | Inhibrx Biosciences GAAP EPS of -$2.84 | 1 | Seeking Alpha | ||
| 14.11.24 | Inhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Third Quarter 2024 Financial Results | 157 | PR Newswire | SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for... ► Artikel lesen | |
| 14.11.24 | Inhibrx Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.24 | Inhibrx Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.08.24 | Inhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights | 314 | PR Newswire | SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
Das Unternehmen INHIBRX BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 11,460 Euro und damit -0,09 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.
